These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23313657)

  • 21. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The acquisition of herpes simplex virus during pregnancy.
    Brown ZA; Selke S; Zeh J; Kopelman J; Maslow A; Ashley RL; Watts DH; Berry S; Herd M; Corey L
    N Engl J Med; 1997 Aug; 337(8):509-15. PubMed ID: 9262493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
    Jones CA; Cunningham AL
    Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
    Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
    J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.
    Koelle DM; Magaret A; McClurkan CL; Remington ML; Warren T; Teofilovici F; Wald A
    Clin Vaccine Immunol; 2008 May; 15(5):773-82. PubMed ID: 18353920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy.
    Oppermann M; Fritzsche J; Weber-Schoendorfer C; Keller-Stanislawski B; Allignol A; Meister R; Schaefer C
    Vaccine; 2012 Jun; 30(30):4445-52. PubMed ID: 22564554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
    Simms JR; Heath AW; Jennings R
    J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
    Awasthi S; Friedman HM
    J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?
    Halford WP
    Expert Rev Vaccines; 2014 Jun; 13(6):691-710. PubMed ID: 24837838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.